Mangalam Drugs & Organics Limited (MANGALAM) Financial History

Name: Mangalam Drugs & Organics Limited (MANGALAM) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-09-20

Mangalam Drugs & Organics Limited (MANGALAM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Mumbai, India with about 319 employees. Its market capitalization is roughly ₹542 million. In the fiscal year ended 2026-03-31, MANGALAM reported ₹2.3B in revenue and (₹444M) in net income.

Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India.

Interactive charts & full statements →

MANGALAM Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Total Revenue	₹2.3B	₹3.2B	₹3.7B	₹3.7B
Gross Profit	₹583M	₹1.2B	₹1.0B	₹987M
Operating Income (EBIT)	(₹323M)	₹168M	₹10M	₹146M
Net Income	(₹444M)	₹67M	(₹91M)	₹13M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MANGALAM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2024-12-31
Total Revenue	₹571M	₹673M	₹584M	₹493M	₹572M	—
Gross Profit	₹225M	₹201M	₹213M	₹162M	₹160M	—
Operating Income (EBIT)	(₹32M)	(₹103M)	(₹59M)	(₹75M)	(₹91M)	—
Net Income	(₹76M)	(₹134M)	(₹98M)	(₹74M)	(₹138M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MANGALAM Free Cash Flow History

MANGALAM Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹3.1B	₹3.7B	₹3.3B	₹3.6B	—
Total Liabilities	₹2.1B	₹2.2B	₹2.0B	₹2.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MANGALAM viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

1652 · Fusen Pharmaceutical Company Limited — HK$621 million
TLRY · Tilray Brands, Inc. — $619 million
3737 · Zhongzhi Pharmaceutical Holdings Limited — HK$607 million
EOLS · Evolus, Inc. — $600 million
BIOFILCHEM · Biofil Chemicals and Pharmaceuticals Limited — ₹534 million
EVT · Evotec SE — €518 million
KMDA · Kamada Ltd. — $478 million
VIVIMEDLAB · Vivimed Labs Limited — ₹463 million

← MANE All “M” companies MANGLMCEM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.